Skip to content

Multi center research of Follow-up study of QOL evolution after clinical trial of Transcatheter Arterial Embolization with Embosphere for Polycystic liver disease.

Multi center research of Follow-up study of QOL evolution after clinical trial of Transcatheter Arterial Embolization with Embosphere for Polycystic liver disease. - Follow-up study of QOL evolution after clinical trial of TAE with Embosphere for Polycystic liver disease.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000033069
Enrollment
35
Registered
2018-06-20
Start date
2018-06-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic liver disease or Autosomal dominant polycystic kidney disease with liver cyst

Interventions

None listed

Sponsors

Hokkaido University Hospital
Lead Sponsor
-Tokyo Women&#39
Collaborator
s Medical University Hospital -Niigata University Medical &amp
Collaborator
Dental Hospital -Osaka University Hospital -Juntendo Unversity Hospital -Teikyo University Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Patients who participated in [Multi institutional joint research of efficacy and safety of Transcatheter Arterial Embolization with Embosphere for Polycystic liver disease] or[A study of efficacy and safety of Transcatheter Arterial Embolization (TAE) with Embosphere for Polycystic liver disease] -Patients from whom written informed consent to participate in this trial has been obtained after sufficient explanation receiving and having understanding

Exclusion criteria

Exclusion criteria: -Not eligible for this study based on the decision 's of a physician

Design outcomes

Primary

MeasureTime frame
QOL evolution and Change in QOL evolution after TAE

Secondary

MeasureTime frame
-Liver volume and the volume reduction rate of the liver -Liver cyst volume and the volume reduction rate of the liver cyst -Treatment rerated Adverse events

Countries

Japan

Contacts

Public ContactTakashi Miyakoshi

Hokkaido University Hospital Clinical Research and Medical Innovation Center

mi_taka_1112@huhp.hokudai.ac.jp011-706-7923

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026